Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
The two patients described developed severe bone toxicities including rib fractures, a toe fracture, osteoporotic thoracic collapses, hypercalcemia, and alternated bone biomarkers. These cases highlight the potential skeletal risks associated with dual MAPK and WNT pathway inhibition.
Authors
- Jan H.M. Schellens (ORCID: https://orcid.org/0000-0001-6832-1976)
- Nathalie Bravenboer (ORCID: https://orcid.org/0000-0001-5050-2584)
- Mark T. J. van Bussel (ORCID: https://orcid.org/0000-0003-0048-6314)
- Frans L. Opdam (ORCID: https://orcid.org/0000-0002-9489-6535)
- Natasha M. Appelman‐Dijkstra (ORCID: https://orcid.org/0000-0001-5035-127X)
- Helma van Essen
- Pétur Snæbjörnsson (ORCID: https://orcid.org/0000-0002-1086-8108)
Institutions
- Utrecht University (NL)
- Leiden University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- Oncode Institute (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/anticanres.17677
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05